News | Left Atrial Appendage (LAA) Occluders | August 06, 2020

Conformal Medical Secures $85 Million in Funding for Left Atrial Appendage Occluder Trial

Funding will support U.S. pivotal trial of CLAAS Stroke Prevention Technology

The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy. #LAA #LAAC

The Conformal Medical CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy.


August 6, 2020 – Conformal Medical Inc. announced it secured $85 million in Series C financing to support the company’s U.S. pivotal trial of its novel CLAAS device, a next-generation transcatheter left atrial appendage (LAA) closure occluder for patients with atrial fibrillation (AF). LAA occlusion allows AFib patients to go off of life-long anticoagulation therapy.

The financing syndicate included participation from new investors Fidelity Management and Research Company LLC and an undisclosed strategic investor, as well as Catalyst Health Ventures (CHV) and many returning Series A and B investors. 

“We are extremely pleased with the strong support of our investment partners, validating the potential of our next-generation technology in the growing LAAC market,” commented Andy Levine, president and CEO of Conformal. “With this significant raise, we look forward to initiating our pivotal trial and taking the next step to establish the CLAAS implant as a cornerstone stroke reduction strategy for patients with AFib.”

Current risk-reduction strategies have significant limitations and leave a clear unmet need in this space,” said Joshua Phillips, managing partner at Catalyst Health Ventures. “The CLAAS technology provides a differentiated solution and we are excited to strengthen our partnership with this proven team and welcome our new funding partners.”

The CLAAS system features a proprietary foam-based architecture designed to accommodate most anatomies with only two sizes and simplified delivery without the need for procedural transesophageal echo (TEE) allowing physicians to perform LAAC without general anesthesia.

Conformal’s randomized pivotal trial is expected to enroll over 1,300 patients at multiple sites globally beginning in early 2021, to investigate the safety and effectiveness of the CLAAS technology, as compared to Boston Scientific’s Watchman products.

“The LAA, is a pouch off the left atrium where clots associated with stroke form in patients with AFib. First generation technology has demonstrated effectiveness compared to oral anticoagulation and fueled early market growth, despite procedural limitations” explained Aaron V. Kaplan, M.D., professor of medicine at Dartmouth and Conformal’s co-founder and chief medical officer. “The CLAAS technology aims to address these limitations and enable physicians to routinely close the LAA without general anesthesia.”

More than 6 million people in the United States suffer from AFib, placing them at an increased risk of stroke.[1] Current standard of care for stroke prevention is chronic oral anticoagulants, which are not well accepted by patients due to concern about associated risk of bleeding. Left atrial appendage closure (LAAC) is emerging as an important alternative to blood thinners for preventing strokes in patients with AFib. Currently, first-generation LAAC devices are an estimated $600 million global market and are expected to grow to over $1 million in the next five years.

For more information: https://conformalmedical.com/

Reference:

1. https://www.cdc.gov/dhdsp/data_statistics/fact_sheets/fs_atrial_fibrillation.htm
 


Related Content

News | Atrial Fibrillation

March 30, 2023 —Vektor Medical has announced that use of its vMap arrhythmia mapping system during complex atrial ...

Home March 30, 2023
Home
News | Atrial Fibrillation

March 27, 2023 — Patients with atrial fibrillation (AF) benefit from early rhythm control therapy. It reduces ...

Home March 27, 2023
Home
News | Atrial Fibrillation

March 9, 2023 — People with a recent diagnosis of atrial fibrillation (AF), the most common irregular heart rhythm, have ...

Home March 09, 2023
Home
News | Atrial Fibrillation

March 8, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 08, 2023
Home
News | Atrial Fibrillation

March 6, 2023 — A new ablation technology known as pulsed field ablation was successful at eliminating episodes of ...

Home March 06, 2023
Home
News | Atrial Fibrillation

February 14, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 14, 2023
Home
News | Atrial Fibrillation

February 9, 2023 — The Cardiomatics certified online SaaS platform provides world-class Holter ECG analytics to support ...

Home February 09, 2023
Home
News | Atrial Fibrillation

February 6, 2023 — In the largest genetic study of heart arrhythmia to date, researchers led by Kazuo Miyazawa and Kaoru ...

Home February 06, 2023
Home
News | Atrial Fibrillation

February 2, 2023 — Abbott today announced two approvals as part of its growing suite of electrophysiology products in ...

Home February 02, 2023
Home
News | Atrial Fibrillation

February 1, 2023 — Periodontitis, a gum disease, can lead to a litany of dental issues from bad breath to bleeding and ...

Home February 01, 2023
Home
Subscribe Now